Literature DB >> 26925875

Paving the TRAIL to anti-fibrotic therapy.

Maria Eugenia Guicciardi1, Gregory J Gores1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26925875      PMCID: PMC4917457          DOI: 10.1002/hep.28520

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  12 in total

Review 1.  Is TRAIL hepatotoxic?

Authors:  G J Gores; S H Kaufmann
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

2.  Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.

Authors:  Yumin Oh; Ogyi Park; Magdalena Swierczewska; James P Hamilton; Jong-Sung Park; Tae Hyung Kim; Sung-Mook Lim; Hana Eom; Dong Gyu Jo; Choong-Eun Lee; Raouf Kechrid; Panagiotis Mastorakos; Clark Zhang; Sei Kwang Hahn; Ok-Cheol Jeon; Youngro Byun; Kwangmeyung Kim; Justin Hanes; Kang Choon Lee; Martin G Pomper; Bin Gao; Seulki Lee
Journal:  Hepatology       Date:  2016-03-03       Impact factor: 17.425

3.  Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Su Young Chae; Tae Hyung Kim; Kyeongsoon Park; Cheng-Hao Jin; Sohee Son; Seulki Lee; Yu Seok Youn; Kwangmeyung Kim; Dong-Gyu Jo; Ick Chan Kwon; Xiaoyuan Chen; Kang Choon Lee
Journal:  Mol Cancer Ther       Date:  2010-06-01       Impact factor: 6.261

4.  Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity.

Authors:  Harmeet Malhi; Fernando J Barreyro; Hajime Isomoto; Steven F Bronk; Gregory J Gores
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

5.  A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice.

Authors:  Juan E Puche; Youngmin A Lee; Jingjing Jiao; Costica Aloman; Maria I Fiel; Ursula Muñoz; Thomas Kraus; Tingfang Lee; Hal F Yee; Scott L Friedman
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

6.  Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.

Authors:  Svetlana Radaeva; Rui Sun; Barbara Jaruga; Van T Nguyen; Zhigang Tian; Bin Gao
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

7.  Hyaluronic acid-tumor necrosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis.

Authors:  Jeong-A Yang; Won Ho Kong; Dong Kyung Sung; Hyemin Kim; Tae Hyung Kim; Kang Choon Lee; Sei Kwang Hahn
Journal:  Acta Biomater       Date:  2014-10-13       Impact factor: 8.947

8.  Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis.

Authors:  Pavel Taimr; Hajime Higuchi; Eva Kocova; Richard A Rippe; Scott Friedman; Gregory J Gores
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

9.  Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis.

Authors:  Petra Hirsova; Samar H Ibrahim; Steven F Bronk; Hideo Yagita; Gregory J Gores
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

10.  Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.

Authors:  Christine C Hsu; Juliane S Troeger; Ingmar Mederacke; Peter Huebener; Xueru Mu; Dianne H Dapito; Jean-Philippe Pradere; Robert F Schwabe
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.